{"id":15293,"date":"2021-06-18T10:18:56","date_gmt":"2021-06-18T08:18:56","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=15293"},"modified":"2021-06-18T10:18:56","modified_gmt":"2021-06-18T08:18:56","slug":"yescarta-axicabtagene-ciloleucel-de-kite-ameliore-sensiblement-la-survie-par-rapport-aux-therapies-actuelles-chez-les-patients-atteints-de-lymphome-folliculaire-refractaire-ou-en-rechute-2","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/yescarta-axicabtagene-ciloleucel-de-kite-ameliore-sensiblement-la-survie-par-rapport-aux-therapies-actuelles-chez-les-patients-atteints-de-lymphome-folliculaire-refractaire-ou-en-rechute-2\/","title":{"rendered":"Yescarta\u00ae (axicabtagene ciloleucel) de kite am\u00e9liore sensiblement la survie par rapport aux th\u00e9rapies actuelles chez les patients atteints de lymphome folliculaire r\u00e9fractaire ou en rechute"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:calc( 1240px + 0px );margin-left: calc(-0px \/ 2 );margin-right: calc(-0px \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:0px;--awb-margin-bottom-large:0px;--awb-spacing-left-large:0px;--awb-width-medium:100%;--awb-spacing-right-medium:0px;--awb-spacing-left-medium:0px;--awb-width-small:100%;--awb-spacing-right-small:0px;--awb-spacing-left-small:0px;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p><em>&#8211; Les donn\u00e9es confirment que l&#8217;axicabtagene ciloleucel offre une am\u00e9lioration significative des options th\u00e9rapeutiques pour les patients atteints de lymphome folliculaire r\u00e9fractaire ou en rechute.<\/em><\/p>\n<p><em>&#8211; Abstract pr\u00e9sent\u00e9 en late-breaker lors de la conf\u00e9rence 2021 de l&#8217;Association europ\u00e9enne d&#8217;h\u00e9matologie (EHA).<\/em><\/p>\n<p>Kite, soci\u00e9t\u00e9 du groupe Gilead, a annonc\u00e9 les r\u00e9sultats d&#8217;une analyse comparant les r\u00e9sultats avec l&#8217;axicabtagene ciloleucel (Yescarta\u00ae) dans l&#8217;essai pivot ZUMA-5 chez des patients suivis pendant 18 mois au minimum, \u00e0 un \u00e9chantillon pond\u00e9r\u00e9 de patients de la cohorte internationale de contr\u00f4le externe SCHOLAR-5. Compar\u00e9s \u00e0 ceux de la cohorte contr\u00f4le, les patients atteints de lymphome folliculaire (LF) r\u00e9fractaire ou en rechute recevant l&#8217;axicabtagene ciloleucel dans le cadre de l&#8217;essai ZUMA-5 ont montr\u00e9 des r\u00e9sultats sup\u00e9rieurs en termes de survie globale (OS) et de survie sans progression (PFS). Les donn\u00e9es ont \u00e9t\u00e9 pr\u00e9sent\u00e9es en <em>late-breaker<\/em>lors du 26<sup>\u00e8me<\/sup>Congr\u00e8s annuel virtuel de l&#8217;Association europ\u00e9enne d&#8217;h\u00e9matologie (EHA 2021), (Abstract n\u00b0LB1904).<\/p>\n<p><em>D&#8217;apr\u00e8s un communiqu\u00e9 de presse de Kite, le 18 juin 2021<\/em><\/p>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[21],"tags":[],"ppma_author":[442],"class_list":["post-15293","post","type-post","status-publish","format-standard","hentry","category-communique-de-presse","author-marion"],"aioseo_notices":[],"authors":[{"term_id":442,"user_id":2,"is_guest":0,"slug":"marion","display_name":"HematoStat.net (M)","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png"},"first_name":"HematoStat.net (M)","last_name":"","user_url":"","description":""}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=15293"}],"version-history":[{"count":0,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15293\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=15293"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=15293"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=15293"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=15293"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}